China: Production of Biopharmaceuticals Clover Biopharmaceuticals Selects GE Biomanufacturing Platform
Editor: Alexander Stark
Clover Biopharmaceuticals has selected GE Healthcare’s Flexfactory, a biomanufacturing platform based on single-use technologies, for its new facility located in Changxing, Zhejiang in China.
Clover Biopharmaceuticals’ new production facility will be located in one of the national economic development zones in China, Changxing Economic and Technological Development Zone.
(Source: GE Healthcare)
Chalfont St Giles/UK and Changxing/China — The new facility will mainly be used to produce biological fusion protein products, including innovative drugs and biosimilars. The biomanufacturing facility includes two 2,000-liter bioreactors from GE, and it will be operational in the latter half of 2018.
Clover Biopharmaceuticals’ new production facility will be located in one of the national economic development zones in China, Changxing Economic and Technological Development Zone, where a new biopharmaceutical industrial cluster is being developed. China plans to build up to twenty science parks for biomedicine by 2020 to accelerate local research and development activities. In 2015, the Chinese biopharmaceutical market was valued approximately at $ 13 billion, and the estimated annual growth rate (CAGR) is around 13 % for the next few years.
Dr. Peng Liang, Co-founder, Chairman and President of Clover Biopharmaceuticals said that Flexfactory represents the latest in biomanufacturing technologies, and would help the company to establish flexible production capacity quickly, while fulfilling good manufacturing practices (GMP) requirements.
The first therapeutic product produced using this biomanufacturing platform is SCB-808, a prefilled syringe formulation Enbrel (etanercept) biosimilar candidate for the treatment of rheumatoid arthritis.
Unfold for details of your consent
Stand vom 23.03.2021
Naturally, we always handle your personal data responsibly. Any personal data we receive from you is processed in accordance with applicable data protection legislation. For detailed information please see our privacy policy.
Consent to the use of data for promotional purposes
I hereby consent to Vogel Communications Group GmbH & Co. KG, Max-Planckstr. 7-9, 97082 Würzburg including any affiliated companies according to §§ 15 et seq. AktG (hereafter: Vogel Communications Group) using my e-mail address to send editorial newsletters. A list of all affiliated companies can be found here
Newsletter content may include all products and services of any companies mentioned above, including for example specialist journals and books, events and fairs as well as event-related products and services, print and digital media offers and services such as additional (editorial) newsletters, raffles, lead campaigns, market research both online and offline, specialist webportals and e-learning offers. In case my personal telephone number has also been collected, it may be used for offers of aforementioned products, for services of the companies mentioned above, and market research purposes.
In case I access protected data on Internet portals of Vogel Communications Group including any affiliated companies according to §§ 15 et seq. AktG, I need to provide further data in order to register for the access to such content. In return for this free access to editorial content, my data may be used in accordance with this consent for the purposes stated here.
Right of revocation
I understand that I can revoke my consent at will. My revocation does not change the lawfulness of data processing that was conducted based on my consent leading up to my revocation. One option to declare my revocation is to use the contact form found at https://support.vogel.de. In case I no longer wish to receive certain newsletters, I have subscribed to, I can also click on the unsubscribe link included at the end of a newsletter. Further information regarding my right of revocation and the implementation of it as well as the consequences of my revocation can be found in the data protection declaration, section editorial newsletter.
:quality(80)/p7i.vogel.de/wcms/d5/27/d52718f1b5c0c1326836ec98a3912dbf/0104995823.jpeg "0104995823")
:quality(80)/p7i.vogel.de/wcms/e0/c8/e0c8f10f52ed8e961d2b1929175cbb96/0104994911.jpeg "0104994911")
:quality(80)/p7i.vogel.de/wcms/16/af/16af797a8a1f8bb82362dfa476acb996/0104964405.jpeg "0104964405")
:quality(80)/p7i.vogel.de/wcms/c0/34/c034428f6f7de33dbc90e8b1fdc7fb21/0104949732.jpeg "0104949732")
:quality(80)/p7i.vogel.de/wcms/d9/4b/d94b9122c3c0cb11915ca1e116bea997/0104986115.jpeg "0104986115")
![Dr. E. Poonguzhali has successfully transferred commercially available starting materials to medicinally important 2-acylbenzo[b]thiophenes in the presence of copper acetate & tetrabutylammonium chloride catalytic system.](https://cdn1.vogel.de/ZK7wqjVy7Ps1OSwUs5tXgrNZGEE=/288x162/smart/filters:format(jpg):quality(80)/images.vogel.de/vogelonline/bdb/1964500/1964559/original.jpg "Dr. E. Poonguzhali has successfully transferred commercially available starting materials to medicinally important 2-acylbenzo[b]thiophenes in the presence of copper acetate & tetrabutylammonium chloride catalytic system.")
:quality(80)/images.vogel.de/vogelonline/bdb/1963700/1963740/original.jpg "The high resolution, modern TFT touch display has a multi-lingual user interface and shows all important information at a glance.")
:quality(80)/images.vogel.de/vogelonline/bdb/1963400/1963417/original.jpg "The 700kHz, 260-element histotripsy ultrasound array transducer used in Prof. Xu’s lab.")
:quality(80)/images.vogel.de/vogelonline/bdb/1963800/1963885/original.jpg "Anna-Lisa Paul, left, and Rob Ferl, working with lunar soils in their lab.")
:quality(80)/images.vogel.de/vogelonline/bdb/1962400/1962494/original.jpg "The operating room produces 70 percent of hospitals' greenhouse gas emissions, but two surgeons-in-training have come up with solutions to reduce that number.")
:quality(80)/images.vogel.de/vogelonline/bdb/1960700/1960778/original.jpg "This plant is modeling the latest wearable sensor (right) to monitor water loss from leaves with a smartphone app (left).")
:quality(80)/images.vogel.de/vogelonline/bdb/1958800/1958848/original.jpg "The user-friendly unit, which weighs less than ten kilograms and does not require the use of filters, can be powered by a small, portable solar panel.")
:quality(80)/p7i.vogel.de/wcms/0d/3b/0d3b418adb4c7af71022c52878dd8fdf/0104800005.jpeg "0104800005")
:quality(80)/images.vogel.de/vogelonline/bdb/1963700/1963732/original.jpg)
:quality(80)/images.vogel.de/vogelonline/bdb/1963500/1963506/original.jpg "Healthy adults eating a diverse diet with at least eight to ten grams of soluble fiber a day have fewer antibiotic-resistant microbes in their guts. Soluble fiber is found in foods such as grains, beans, lentils, nuts, and some fruits and vegetables.")
:quality(80)/images.vogel.de/vogelonline/bdb/1963400/1963459/original.jpg "Thermo Scientific Dionex Ionpac CS21-Fast-4m ion exchange column.")
:quality(80)/p7i.vogel.de/wcms/80/94/809443e7ecaec616dc5f4183742f92cb/0105005033.jpeg "0105005033")
:quality(80)/p7i.vogel.de/wcms/2a/d9/2ad9f27ac42afb15a06350c4c5fb17c9/0104994092.jpeg "0104994092")
:quality(80)/p7i.vogel.de/wcms/29/a8/29a87518fdfa5741b9cf4429a448729f/0104917902.jpeg "0104917902")
:quality(80)/p7i.vogel.de/wcms/93/1b/931ba9a54f6fff41d2cdd7cf74a1e174/0104884529.jpeg "0104884529")
:quality(80)/images.vogel.de/vogelonline/bdb/1710600/1710675/original.jpg "Discover how to set yourself up for success when performing balance-based density determination of solids such as jewelry and precious metals.")
:quality(80)/images.vogel.de/vogelonline/bdb/1682500/1682579/original.jpg "The new XPR Analytical balance redesigned to meet the needs of laboratory technicians of working fast and lean.")
:quality(80)/images.vogel.de/vogelonline/bdb/1677000/1677080/original.jpg "Enhance your weighing accuracy, comfort and productivity with the redesigned XPR Analytical balance.")
:quality(80)/images.vogel.de/vogelonline/bdb/1858100/1858139/original.jpg "Biontech aims to develop the first mRNA-based vaccine for Malaria prevention with the initiation of a clinical trial by end of 2022.")
:quality(80)/images.vogel.de/vogelonline/bdb/1900600/1900699/original.jpg "Bilfinger develops, manufactures and assembles modules for biopharmaceutical systems.")